2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144213
    SOS1-IN-10
    		Inhibitor
    SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
    SOS1-IN-10
  • HY-181807
    SOS1/KRAS-IN-2
    		Inhibitor
    SOS1/KRAS-IN-2 (Compound 20) is a SOS1::KRASG12C protein-protein interaction inhibitor with a IC50 of 4.11 nM. SOS1/KRAS-IN-2 blocks the interaction between SOS1 and KRASG12C. SOS1/KRAS-IN-2 induces cell Apoptosis. SOS1/KRAS-IN-2 exhibits anticancer activity against colorectal cancer and tongue squamous cell carcinoma.
    SOS1/KRAS-IN-2
  • HY-182706
    NSC 373981
    		Inhibitor
    NSC 373981 is a CARD11 G4 stabilizer. NSC 373981 stabilizes the CARD11 G4 structure and inhibits CARD11 transcription in cells. NSC 373981 also inhibits BCL2 and MYC. NSC 373981 suppresses the transcription of KRAS and TERT. NSC 373981 exhibits anticancer activity against diffuse large B-cell lymphoma.
    NSC 373981
  • HY-134263
    8-Br-cAMP-AM
    		Agonist
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury.
    8-Br-cAMP-AM
  • HY-143359
    COTI-219
    		Inhibitor
    COTI-219 is an orally active inhibitor of KRAS. COTI-219 has antitumor activity.
    COTI-219
  • HY-146061
    KRAS G12C inhibitor 48
    		Inhibitor
    KRAS G12C inhibitor 48 (compound 6e) is a potent KRAS G12C inhibitor with an IC50 of 639.91 nM. KRAS G12C inhibitor 48 (0-50 µM) shows anti-proliferative activity with IC50s of 0.796, 6.33, 16.14 µM for H358, H23, A549 cells, respectively.
    KRAS G12C inhibitor 48
  • HY-178501
    KRAS-IN-45
    		Inhibitor
    KRAS-IN-45 (Compound 1.019) is a KRAS inhibitor. KRAS-IN-45 can be used for the study of cancers.
    KRAS-IN-45
  • HY-123795
    NY0123
    		Inhibitor
    NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer.
    NY0123
  • HY-153858
    PHI-501
    		Inhibitor
    PHI-501 is a dual inhibitor targeting RAF/DDR. PHI-501 exhibits significant anti-proliferative effects in melanoma cell lines and significantly inhibits the colony formation of drug-resistant cells. PHI-501 strongly inhibits ERK and AKT phosphorylation. PHI-501 downregulates the gene sets in drug-resistant cells of TNFA-NFKB, IL6-JAK-STAT3, and KRAS signaling pathways as well as the epithelial-mesenchymal transition (EMT) signaling pathways. PHI-501 demonstrates significant anti-tumor effects in the SK-MEL3DR xenograft model. PHI-501 can be used for research on the problem of drug resistance in melanoma.
    PHI-501
  • HY-153899
    KRAS G12C inhibitor 59
    		Inhibitor
    KRAS G12C inhibitor 59 is a KRAS G12C inhibitor with anticancer effects (WO2023036282A1, compound II).
    KRAS G12C inhibitor 59
  • HY-145020
    KRAS G12C inhibitor 23
    		Inhibitor
    KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1).
    KRAS G12C inhibitor 23
  • HY-178873
    PROTAC K-Ras Degrader-7
    		Degrader
    PROTAC K-Ras Degrader-7 is a potent PROTAC K-Ras degrader. PROTAC K-Ras Degrader-7 degrades K-Ras through recruiting the Keap1 E3 ubiquitin ligase. PROTAC K-Ras Degrader-7 can be used for research in pancreatic and colorectal cancers.
    PROTAC K-Ras Degrader-7
  • HY-145022
    KRAS G12C inhibitor 25
    		Inhibitor
    KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC50=0.48 nM). From WO2021216770A1 compound 3.
    KRAS G12C inhibitor 25
  • HY-147595
    KRAS G12D inhibitor 15
    		Inhibitor
    KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243). KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KRAS G12D inhibitor 15
  • HY-170785
    pan-KRAS-IN-17
    		Inhibitor
    pan-KRAS-IN-17 (Example 34) is an inhibitor of pan KRAS.
    pan-KRAS-IN-17
  • HY-143604
    KRAS G12D inhibitor 11
    		Inhibitor
    KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52).
    KRAS G12D inhibitor 11
  • HY-162281
    PROTAC SOS1 degrader-6
    		Degrader
    PROTAC SOS1 degrader-6 (compound 23) is an effective SOS1 PROTACs degrader that synergizes with KRASG12C inhibitors. PROTAC SOS1 degrader-6 consists of the target protein ligand (red part) SOS1 Ligand intermediate-7 (HY-169371), E3 ubiquitin ligase ligand (blue part) (S,R,S)-AHPC (HY-125845), and PROTAC linker (black part) 5-Bromopentanoic acid (HY-W016456). Among them, the E3 ubiquitin ligase ligand + linker can form (S,R,S)-AHPC-CO-C4-bromine (HY-169372).
    PROTAC SOS1 degrader-6
  • HY-177762
    Pan-RAS-IN-8
    		Inhibitor
    Pan-RAS-IN-8 (Page 152, third row, third from left to right) is a pan-RAS inhibitor. Pan-RAS-IN-8 blocks the binding of RAS to downstream effector molecules by forming a ternary complex, thereby inhibiting the activation of the MAPK and PI3K-AKT signaling pathways. Pan-RAS-IN-8 can be used for the research of cancer, inflammatory diseases and autoimmune diseases.
    Pan-RAS-IN-8
  • HY-107841
    K-Ras(G12C) inhibitor 6
    		Inhibitor 99.08%
    K-Ras(G12C) inhibitor 6 is a selective and irreversible K-RasG12C inhibitor. K-Ras(G12C) inhibitor 6 can be used for the research of lung cancer.
    K-Ras(G12C) inhibitor 6
  • HY-161714
    HH0043
    		Inhibitor
    HH0043 (Compound 10f) is an orally active and potent SOS1 inhibitor, with IC50 value of 5.8 nM. HH0043 can be used for the research of cancer.
    HH0043
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.